At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
LY2623091 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients
In Brief
A Phase 2 clinical trial evaluating LY2623091 and Eplerenone for Chronic Kidney Disease. Completed, enrolled 42 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this trial is to investigate the safety and efficacy of LY2623091 in males and females with chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesBulgaria, South Africa
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedSep 2011
Primary CompletionMar 2013
TodayJul 2026
First PostedSep 2, 2011
Enrollment StartSep 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.8 years ago
Interventions
LY2623091drug
Administered orally
Eplerenonedrug
Administered orally